Unless Q1 was a disaster $3 would be a pretty attractive entry point considering the stock hasn't seen that since new reimbursements were announced. This is a tiny company with a potentially huge product line that has lots of reasonable upside catalysts (bundled care, greater adoption, higher procedure volume) with the only downside being either 1) A negative clinical trial or 2) management screwing up (much more likely than #1).
That being said, anybody who bets the farm on a company with a market cap under $100M deserves what they get if things go south.
You are the winner of the post of the month being the only post for a month. Might even go to 2 after all the shares that were purchased by people thinking they were going to get rich quick. This is the first time I've ever heard of a company increasing their shares by lowering the amount they can issue. Now that the chart is going down out come the downgrades.